↩ Go Back
Need help?

Bio Diagnostics Businesses for Sale and Investment Opportunities

Showing 1 - 7 of 7 Bio Diagnostics Businesses for Sale and Investment Opportunities. Buy or Invest in a Bio Diagnostic Business.

Filters
  • Bio Diagnostics

 

Bio Diagnostics Company Investment Opportunity in Phoenix, United States

Gene therapy and biomarker/diagnostic company focused on neurological conditions including; ALS, Parkinson's, Alzheimer's and TBI.
- Business primarily focused on gene therapy and biomarker/diagnostic services, with a specific emphasis on neurological conditions such as ALS, Parkinson's, Alzheimer's, and TBI. - Offers biomarker testing as a CRO for pharma and researchers. Additionally, it is involved in the development of Adeno-Associated Viruses (AAVs) for neurodegenerative disorders, with a particular focus on inflammation and targeting neurons and glial cells. - Has patented and licensed technologies from premier research institutions. - The company generates revenue on a per research project basis, with an average project duration of 3 months and an average value ranging from $8,000 to $25,000. It has successfully completed projects for 10 different research companies since its inception. - The company is currently engaged in a gene therapy research project involving 2,600 samples. - There are 2 permanent employees, additionally, we have a few temporary employees/interns as well.
7.9   Phoenix
Run Rate Sales
USD 150 thousand
EBITDA Margin
Nil
Financial Investment
USD 20 Mn for 20%
Contact Business

Bio Diagnostics Company Investment Opportunity in Reading, United Kingdom

Biotech company seeking funds to begin the production of AI-powered remote health monitoring devices.
- Deep biotech company incubated by a leading university. - We have developed a portable device with AI-powered image recognition capabilities that can analyze Full Blood Count tests. The device will help with monitoring a patient's health from home for conditions such as leukemia and other types of cancer. - Patient can run the tests from their home and once the sample is analyzed, the results are deployed to our platform (app and browser), which is only shared with the designated doctor. - We also provide sophistical tools that help the patient and doctors to track and monitor health over time. - Have our own production facility with a capacity for 100 devices per month and the development of the device is already complete. We have also applied for a patent in the UK. - Revenue model: We will charge a monthly subscription of GBP 1,000 for medical professionals and doctors, and GBP 100 for patients. - Cost of production of each unit is around GBP 1,200 and we have already targeted the production of 1,000 pieces for the launch. - Well-experienced team of experts and medical consultants with over 30 years of industry experience.
Biotech company seeking funds to begin the production of AI-powered remote health monitoring devices.
7.4   Reading
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 1.3 Mn for 10%
Contact Business

Bio Therapeutic Drugs Business Investment Opportunity in Manlius, United States

Company developing diagnostics & therapeutics for skin cancer: basal cell carcinoma, squamous cell carcinoma, melanoma.
- The company currently works with pharmaceutical and diagnostic companies, research institutes, CROs, and CDMOs to help them develop molecular bioassays and digital pathology products, and to visualize and analyze the resultant data via AI and ML for the benefit of patients, their family, and their healthcare providers. - Currently, has 3 clients: Klotho Therapeutics Inc. (a biotechnology company in San Diego, CA, USA), Unger Medical PC (a hair restoration medical practice in NY, NY, USA), and Astrix Technology Group (a life sciences strategy, technology, and staffing services company based in Red Bank, NJ, USA). • Target Market: - The business is specialized in developing diagnostics and therapeutics for human basal cell carcinoma, squamous cell carcinoma, and melanoma. This skin cancer group comprises the most diagnosed cancers worldwide of all cancer types with over five million cases diagnosed each year. - The skin cancer therapeutics diagnostics and therapeutics products industry worldwide were worth $8.2 billion USD in 2019 and is projected to reach $15 billion by 2027. This represents a CAGR of 7.5%. - What share of the total skin cancer target market can we estimate is realistic for to obtain? A conservative estimate is that our company should be able to reach $150 million USD in annual revenues by the close of 2028. • Problem or Need: - The main project involves the development of a Skin Cancer Patient Data Blockchain. - Currently there is a serious problem concerning how oncology patients organize and share their medical data, how companies get access to this data, and a lack of return in value to the patients for sharing their personal data. The blockchain is designed to tackle and solve these problems. - The blockchain for skin cancer patients will be comprised of multiple decentralized nodes contributing data to a shared ledger where patients can set up smart contracts to share and control their data. - Skin cancer patients will be able to share their data with research institutions, drug companies, diagnostic companies, contract research organizations, client trials organizers, and other stakeholders. - Also, planning to launch a medium of exchange within the blockchain system to allow patients to be given money for participation in the sharing of their data with the mentioned company stakeholders. - Therefore, the company stakeholders that plan to utilize the patient’s data would provide revenues and income to support the operations of the blockchain. - For example, pharmaceutical companies would be important customers that the business would cultivate as users of the patient’s healthcare data. This is because pharma companies can use this blockchain to discover patients with the right profile for a skin cancer clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. This should greatly streamline for the pharma company the time it takes to enroll the right patients into clinical trials and get them started. • Solution: - What is the core value proposition? For the company stakeholders in the skin cancer patient blockchain, the business is hoping to demonstrate that this blockchain technology will be a way to improve business outcomes through better efficiency, risk management, and security. - For these customers, this will enable them to maintain and capture new sources of profit. At the same time, company stakeholder participation will also grow the business as the integrator and host of the blockchain and result in significant profit growth for the company. • Team: The team is comprised of: - Founder, President, and CEO, a 100% full-time permanent employee has a Ph. D. in Cell and Molecular Biology from St. John’s University (New York, NY), a M. S. in Microbiology & Immunology from Long Island University, and a M. B. A. from Le Moyne College. In addition, he has 20 years of quality assurance and regulatory affairs experience at the Bristol-Myers Squibb Company, Charles Rivers Laboratories, and Vybion, Inc. This includes moving numerous human therapeutic products from R&D, through clinical trials, and into the marketplace via approval by the US FDA and worldwide regulatory bodies. In addition to the above experience, and an addition 18 year of experience in human therapeutics research and development and in the management of laboratory-based cell culture, toxicological, or bioassay projects within the biopharmaceuticals industry. However, he is a Senior Member of the food, drugs & cosmetics section of the American Society for Quality (ASQ), and a society member of The American Association for the Advancement of Science (AAAS). - The President of Hillberg Consulting is a part-time, non-permanent hourly contract employee of R&D department. She is an accomplished executive and board member with a reputation for delivering bottom-line profitability while building the infrastructure to support growth and success. She has served at Johnson & Johnson Ortho Clinical Diagnostics as VP of R&D, and as Chief Technology, Officer at Carestream Health. Holly has a B. S. in Chemical Engineering from Michigan Technology University and a M. S. in Electrical Engineering from Rochester Institute of Technology. - Marketing Consultant - part-time, non-permanent hourly employee. He is a professional engineer and entrepreneurial executive with focus on emerging technology solutions applied to real world problems. He has substantial experience in team building and in developing market strategies & partnerships. This includes over two decades of technology & networks business planning, development, & implementation. He has a Masters in Entrepreneurial Studies - MIT Sloan School of Management, and M. S. & B. S. in Engineering from Syracuse U. and Utica College. - Blockchain Development Technical Project Management Consultant - Part-time, non-permanent hourly employee that is a contractor from EffectiveSoft Corporation, San Diego, CA. She has eight years of experience as VP of Service Delivery and as the Head of Sales for enterprise level software solutions at Effective Soft Corp. She has a M. B. A. from The University of Manchester and a B. S. degree from Minsk State Linguistics U. – Legal Counsel - Part-time, non-permanent hourly contract employee. He holds the Juris Doctor from Boston College Law School, and B. A. in Political Science from Binghamton University. He is a Partner at Newman & Lickstein, with eight years of experience in representing technology companies and investors in licensing, IP development, real estate, mergers & acquisitions, and business litigation. - Demonstrating results to stakeholders will be the key to success. For skin cancer, there is a lot of data collected from various heterogeneous sources – pathology imaging data, genetic testing, surgery, drugs intervention, payer, and insurance information, etc. - Some companies are using a website or app to meet the social needs of patients to discuss their concerns with other patients or a few qualified physicians. No competitor is comprehensively focusing on skin cancer data & treatment to the level that we do. Possible competitors have thus not yet integrated the patient data, shared consent, and the patient monetization blocks together into a comprehensive and workable blockchain system for skin cancer patients, or for any segment of the oncology market, for that matter. - This team, on the other hand, has decades of experience in oncology research, the development of products and services for cancer patients, in oncology clinical biomedicine and in oncology marketing, and that makes the company well-equipped to solve the problems around skin cancer patient data acquisition, its organization, and its beneficial use for the patients and for their healthcare providers. For example, regarding the latter, the company also harnesses artificial intelligence (AI) and machine learning (ML) to extract relevant data from the patient’s database that will help healthcare providers to better understand the patient’s tumor and the tumor microenvironment (i. e. , tumor growth, cellular migration, blood supply to the tumor, subcellular trafficking, and tumor metastasis), drug efficacy (including drug penetration into the tumor, possible tumor shrinkage or tumor death, and drug toxicity, and side effects), or the immediate or long term results of surgical intervention. - When competitors enter this specific market, the business plans to stand out by utilizing a value-based strategy that clearly displays our brand and the above competitive advantage. • Traction: - Currently works with pharmaceutical and diagnostic companies, research institutes, and contract research development and manufacturing companies to help them obtain and organize their molecular bioassays and pathology data. We propose to utilize this traction and intercompany personal connections to gain and grow customers that will use and pay for patient data on the blockchain. - Also use social media & patient advocacy organization to recommend the blockchain to skin cancer patients so that we can grow the patient database. - The company is also a member of the Hyperledger Foundation Healthcare Special Interest Group. Hyperledger, as part of the Linux Foundation, provides technology leaders a uniquely open and collaborative international community from which to develop, validate, and field enterprise-grade blockchain technology solutions. It is the mandate of the Hyperledger Healthcare Special Interest Group (HC-SIG) to represent healthcare professionals and technologists, to globally unite these individuals, and to advance the state of the healthcare industry through the implementation of technology solutions using blockchain technologies in general, and the umbrella of Hyperledger frameworks and toolsets specifically. • Revenue Model: - Within the ecosystem surrounding the above patients, who would buy/lease the skin cancer blockchain services that the company wish to market? In this blockchain system, individuals will be allowed to store and monetize their own health data including blood test results, medical history, genetic profile, skin photographs, pathology images and other sensitive information. - In the healthcare marketplace, cancer patients would be paid in stablecoin currency to lease their individual data to companies for a certain amount of time. - Pharmaceutical (pharma) companies would be important customers that the company would cultivate as users of the patient’s permitted healthcare data. - Blockchain can help pharma companies discover patients with the right profile for a clinical trial, even if those patients were not actively searching to participate in a clinical trial for a product from which the pharma or diagnostics company might benefit. - According to Milind Kamkolkar, chief data officer at Sanofi, patients could be prompted based on their data to join a clinical trial, thereby also accelerating the process and accuracy of trial recruitment. Using this blockchain if a person declines, no personal information will be shared, and the person's identity will remain private. If the person agrees, the overall process will move faster by abolishing the need for intermediaries. - For pharma companies, better inclusion in clinical trials and better reproducibility for studies can reduce the time and money needed to develop new drugs. - Besides pharma companies, research institutes will be willing to pay for the data from skin cancer patients, and the introduction of our blockchain-based data ecosystem may help ensure that the individuals take control over their data and companies and research institutions may acquire data more freely after the latter have obtained consent from individual patients. - How are the products and services going to generate revenue? The most straightforward way to generate revenue is to have the blockchain client customers pay for the products and services that exceeds by a large margin what it costs to develop and operate the blockchain (a cost-plus strategy). - When competitors enter this specific market, plan to stand out by utilizing a value-based strategy that clearly displays the brand and competitive advantage. • Market Projections: - What share of the total skin cancer blockchain target market can we estimate is realistic for to obtain? The global skin cancer blockchain customer market size stood at USD 8.19 billion in 2019 and is projected to reach USD 14.55 billion by 2027, exhibiting a CAGR of 7.5% during the forecast period. A conservative estimate is that the company should be able to reach $150 million in annual revenues in 4 years. - These financial projections would be possible because of the company participating and partnering with individuals and companies within the oncology community to create superior value for the products and services. - Over the next 4 years, the company anticipates receiving funding from investors, and revenues from pharmaceutical companies and research institute customers. - However, expenditures are also expected to increase. Expenses incurred will be for the development of products and services, and for personnel, equipment, supplies, business development & marketing. • Competition: - Have identified Nebula Genomics and Longenesis as competition. These two leading firms in artificial intelligence and blockchain technology for healthcare, are developing a platform for the storage and exchange of genomic data. - Nebula Genomics is a San Francisco-based biotechnical company that uses blockchain to “build a marketplace” for clinical genetics data. - Longenesis is a Hong Kong-based partnership between Insilico Medicine and the Bitfury Group, which makes blockchain platforms for the exchange of health data. - The above companies will reportedly apply artificial intelligence and blockchain technology to develop a platform for individuals and large data providers to store, manage, exchange, and profit from genomic and other types of clinical data. To automate data acquisition, the project developed by both Nebula Genomics and Longenesis will utilize smart contracts. - Unlike the Nebula Genomics and Longenesis blockchains, this blockchain project will be focused on oncology patients and the ecosystem around them rather than on a multitude of disease sectors. - In addition to Nebula Genomics and Longenesis, the U. S. -based life science research marketplace, Scientist. com, has revealed the development of a pharmaceuticals blockchain platform. This latter blockchain-powered platform is reportedly designed to track and protect pharmaceutical data. Thus, the Scientist. com DataSmart TM platform enables pharmaceutical and biotech companies to demonstrate that critical supplier information and important research data has not been tampered with and remains unaltered before submission to regulators such as the FDA and the EMEA. - However, the above platforms do not adequately address the pressing concerns of cancer patients regarding the control and sharing of their personal data. Competitive Advantage: • Strategy. Specifically for oncology blockchain products, the major company players that may join our blockchain to gain access to data from skin cancer patients include: Almirall S. A. Amgen, Inc. Boehringer Ingelheim GmbH. Bristol-Myers Squibb Company. Eli Lilly and Company. Elekta AB. F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc. Merck & Co. , Inc. Mylan NV. Novartis AG. Pfizer. Regeneron. Sanofi. Sun Pharmaceutical Industries Ltd. Varian Medical Systems, Inc. Sensus Healthcare. ICAD, Inc. Accuray, Inc.
Company developing diagnostics & therapeutics for skin cancer: basal cell carcinoma, squamous cell carcinoma, melanoma.
9.5   Manlius
Run Rate Sales
USD 26 thousand
EBITDA Margin
35 %
Financial Investment
USD 1 Mn for 25%
Contact Business

Bio Diagnostics Company Investment Opportunity in Uxbridge, United Kingdom

Invest in the UK healthcare business for potential growth in the gene therapy field.
• Healthcare business located in the United Kingdom offering gene therapy products and services. • University spin-out with patented technology and other scientific developments in the pipeline. • Aiming to improve the safety and efficiency of gene therapy. • Top selling products will be tests to ascertain if a person can repair their DNA, testing if a virus used to deliver a gene therapy will actually be safe. • Gene therapy and CAR-T therapy is a rapidly growing field, offering great potential for the company. • Experienced team of scientists and engineers ready to create a successful business. The business is not operational currently. • Unique products and services that can be marketed to potential customers worldwide.
7.7   Uxbridge
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 650 K for 25%
Contact Business

Bio Diagnostics Company Investment Opportunity in Bangalore, India

Investor sought by a bootstrapped R&D lab developing tools for precision medicine in cancer.
- Bio-diagnostic research company developing a cancer diagnosis, prognosis, and discovery tool. - Promoter has set up a laboratory with his own funds. - The laboratory has the basic equipment necessary to develop the product. - The lab has a collaboration with a French laboratory. - Developing proof of concept as of now. - We require funds to hire technical manpower and conduct trials in hospitals. - The promoter has a doctorate in Neurobiology from France with 15 years of industrial experience in similar areas. They have experience in oncology as well. - Looking for investors to bring the ideas into reality. The investor will receive a 30% stake in the company.
6.3   Bangalore
Run Rate Sales
Nil
EBITDA Margin
Nil
Financial Investment
USD 600 K for 30%
Contact Business

Bio Diagnostics Business Investment Opportunity in Pune, India

Variety of diagnostic kits for healthcare, infertility, drones, agriculture, food, ngs, research and biotechnology.
- Our company is essentially a biotechnology organization that sells proprietary diagnostic kits for healthcare and biotechnology research kits along with services. - These kits allow our customers to evaluate various parameters by themselves. - We have more than 40 in-house researched products. Manufacturing is done at our own premises. - Our products are sold to 32 distributors who further sell them at pharmacies and hospitals across India. Kits are also sold in Saudi Arabia, Dubai, Ukraine, Sudan and Zimbabwe. We do not sell our products directly to any customers. - Revenue plummeted this year due to the effect of the pandemic on the market. - The business is extremely valuable due to our vast array of products, IP, and enormous growth potential in the future.
Variety of diagnostic kits for healthcare, infertility, drones, agriculture, food, ngs, research and biotechnology.
7.0   Pune
Run Rate Sales
USD 1.2 million
EBITDA Margin
10 - 20 %
Financial Investment
USD 600 K for 15%
Contact Business

Bio Diagnostic Franchise Opportunity

Enbiosis Biotechnology, Established in 2021, 13 Franchisees, London Headquartered
  • 10+ introductions
  • 700+ Page Views
  • 200+ Investor Views
- Company and product: Enbiosis has developed an advanced artificial intelligence algorithm that analyzes the human gut microbiome and recommends personalized food and supplements to individuals to improve their gut health and address chronic disorders such as gastrointestinal disorders, skin-related disorders, and weight loss issues. - How it works: Patients/customers send their stool samples to any NGS laboratory in their region. Enbiosis takes the raw bacterial DNA data to the local server (to avoid data protection risks) and creates a personalized report, which is sent to patients and, if required, their practitioners within minutes. - Business model: Enbiosis's microbiome test can be sold through practitioners and/or directly to customers, depending on market dynamics. Practitioners can prescribe the test to patients to generate a personalized diet plan, or patients can follow their personalized nutrition guide through the app to improve general well-being and solve their problems. - Main differentiation: Enbiosis is the only clinically proven precision diet technology that claims to address the main cause of chronic disorders. It has conducted three clinical trials and published the results in peer-reviewed journals. Enbiosis's claims are backed by scientific evidence. - The main reason why investors should consider Enbiosis: In recent years, the number of people seeking to address their health problems through alternative methods instead of pharmaceuticals has been increasing. The challenge in alternative medicine is the lack of scientific data. Enbiosis serves as a bridge between alternative medicine and conventional medicine, and there is significant market potential for Enbiosis. For example, Enbiosis has proven the effectiveness of its technology in patients with IBS, who make up about 10% of the population. Offering individuals the opportunity to solve their chronic problems simply by changing their diet within a specific period is something they are interested in and willing to try. - Additionally, investors/distributors can offer a routine follow-up program to check gut health and prevent any kind of diseases, opening the door to long-term recurring revenue. - We have a trade registration certificate to operate.
Enbiosis Biotechnology, Established in 2021, 13 Franchisees, London Headquartered
9.5   Expanding in Canada
Exp Monthly Sales
USD 190 thousand
Space Required
0 - 80 Sq Ft
Investment Required
USD 60 K
Contact Company

Frequently
Asked
Questions

  • How many bio diagnostics businesses for sale and investment opportunities are listed on SMERGERS?
    There are 7 active and verified bio diagnostics businesses for sale and investment opportunities listed on SMERGERS as of 29 March 2024.
  • What level of due diligence does SMERGERS conduct on the businesses/member?

    SMERGERS scrutinizes all profiles and only features a select group of businesses, investors, advisors that meet a basic requirement. When required, certain members may have submitted some form of proof …read more

  • How active are the business profiles listed on SMERGERS?

    We regularly filter out businesses which are inactive or have already closed a transaction. Typically, if the business is actively looking to sell/raise capital, the status is shown in green.

  • How can I be sure about privacy and confidentiality?

    We understand the level of confidentiality required in strategic transactions and we strive to provide a safe and secure experience for our members. Please review our privacy policy. We …read more

  • How can I contact a business listed on SMERGERS?

    You need to be logged in before you connect with a business. Click here to register and message the business If you are already logged in, please use the contact …read more

  • Should you buy an existing business or start a business from scratch?

    Buying an existing business is generally an easier way to start a business with an immediate head start. It saves valuable time and administrative efforts, considering starting from scratch is …read more

  • How successful has SMERGERS been in helping its users successfully close a deal?

    SMERGERS is a discovery and matchmaking platform with a global reach. It helps in connecting Businesses, Investors, Acquirers, Lenders, M&A Advisors and Boutique Investment Banks across locations, industries and transactions. …read more

  • Show more